The Life Sciences Report Examines Actinium's Radioimmunotherapies
SAN FRANCISCO, CA--(Marketwired - August 18, 2016) - Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. (NYSE MKT: ATNM) is in position to benefit, according to company executive chairman Sandesh Seth. With two assets …